Identification of biomarkers associated with the efficacy of treatment with biological medicinal products in patients with severe asthma. (Q3150755)
Jump to navigation
Jump to search
Project Q3150755 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Identification of biomarkers associated with the efficacy of treatment with biological medicinal products in patients with severe asthma. |
Project Q3150755 in Spain |
Statements
41,000.0 Euro
0 references
82,000.0 Euro
0 references
50.0 percent
0 references
1 January 2019
0 references
31 March 2022
0 references
FUNDACION UNIVERSITARIA SAN PABLO-CEU
0 references
40°25'0.12"N, 3°42'12.89"W
0 references
28079
0 references
El asma es una enfermedad crónica inflamatoria que afecta en la actualidad a 334 millones ocasionando una importante morbi-mortalidad y enorme coste económico al SNS. La mayoría de los pacientes diagnosticados con asma, pueden ser tratados de forma eficaz con corticoides inhalados y broncodilatadores. Sin embargo, existe un grupo de pacientes que no se controlan con este tratamiento, los pacientes con asma grave no controlada. Presentan una mayor tasa de mortalidad y un elevado número de comorbilidades, tales como la polipósis nasal o la intolerancia a AINES. Dentro de las nuevas estrategias terapéuticas dirigidas a controlar estos casos más graves, están los medicamentos biológicos como anti-IgE (Omalizumab) y anti-IL5 (Mepolizumab, Reslizumab). Sin embargo, no se dispone de la información necesaría para hacer un uso racional de estos. En este proyecto se propone que es posible identificar un panel de biomarcadores que puedan usarse para definir: el tiempo de tratamiento óptimo con los medicamentos biológicos Omalizumab y Mepolizuman, las rutas biológicas alteradas con este tratamiento y los biomarcadores de utilidad para predecir eficacia y para la monitorización de estos tratamientos en pacientes con asma grave no controlado. La optimización del uso de estos tratamientos supondría una mejora significativa en la calidad de vida de los pacientes a medio-largo plazo y un ahorro considerable para el SNS. (Spanish)
0 references
Asthma is a chronic inflammatory disease that currently affects 334 million, causing a significant morbidity-mortality and enormous economic cost to the SNS. Most patients diagnosed with asthma can be effectively treated with inhaled corticosteroids and bronchodilators. However, there is a group of patients who are not controlled with this treatment, patients with severe uncontrolled asthma. They have a higher mortality rate and a high number of comorbidities, such as nasal polypose or NSAID intolerance. Among the new therapeutic strategies aimed at controlling these more serious cases are biological medicines such as anti-IgE (Omalizumab) and anti-IL5 (Mepolizumab, reslizumab). However, the information needed to make rational use of these is not available. In this project it is proposed that it is possible to identify a panel of biomarkers that can be used to define: the optimal treatment time with the biological medicines Omalizumab and Mepolizuman, the biological pathways altered with this treatment and the useful biomarkers for predicting efficacy and for monitoring these treatments in patients with severe uncontrolled asthma. Optimising the use of these treatments would result in a significant improvement in the quality of life of patients in the medium to long term and a considerable saving for NHS. (English)
12 October 2021
0 references
Madrid
0 references
Identifiers
PI18_01467
0 references